Felbamate is not a controlled substance. It carries no DEA schedule designation, meaning it is not classified alongside drugs that have recognized potential for abuse or dependence. That said, felbamate is far from an ordinary prescription. It carries some of the most serious safety warnings the FDA can place on a medication, which is why many people assume it might be tightly restricted.
Why Felbamate Is Not Scheduled
The DEA places drugs on controlled substance schedules (I through V) based on their potential for abuse, physical dependence, and accepted medical use. Felbamate does not produce the kind of euphoria, sedation, or reward-seeking behavior that triggers scheduling. It works by dampening overactive electrical signals in the brain, both by blocking excitatory pathways and by boosting the brain’s natural calming mechanisms. While that second effect is sometimes compared to how barbiturates work, felbamate does not carry the same abuse profile.
Several other seizure medications are scheduled. Phenobarbital is Schedule IV. Pregabalin (Lyrica) and lacosamide (Vimpat) are Schedule V. Perampanel (Fycompa) is Schedule III. These drugs all have documented misuse potential that felbamate lacks. So while your pharmacist won’t need to follow the extra dispensing rules that apply to controlled substances, felbamate still requires a standard prescription and close medical oversight.
What Actually Restricts Felbamate
The restrictions on felbamate come not from the DEA but from the FDA, in the form of a boxed warning, the agency’s strongest safety alert. Felbamate is linked to a significantly increased risk of two life-threatening conditions: aplastic anemia (a failure of the bone marrow to produce enough blood cells) and acute liver failure.
The numbers put this in perspective. Aplastic anemia occurs in an estimated 127 out of every million felbamate users per year, with the range spanning roughly 27 to 209 per million. For liver failure, the rate is approximately 1 case for every 18,500 to 25,000 people exposed. Among reported cases of felbamate-related liver failure, about 67% resulted in death or required a liver transplant, typically within five weeks of the first signs of trouble. Liver problems most commonly appear one to six months after starting the drug, with the earliest cases showing up around three weeks in.
Because of these risks, the FDA requires that patients (or their parents or guardians) receive a written informed consent form and have a thorough discussion about the dangers before starting treatment. Doctors must also order blood work before prescribing felbamate and continue monitoring blood counts and liver enzymes throughout treatment and for a period after stopping.
Who Felbamate Is Prescribed For
Felbamate is never a first-choice epilepsy treatment. It is reserved for people whose seizures have not responded adequately to safer alternatives and whose condition is severe enough that the risks of aplastic anemia and liver failure are considered acceptable given the potential benefit. In adults, it is used alone or alongside other medications to control partial seizures. In children, it treats both partial and generalized seizures associated with Lennox-Gastaut syndrome, a particularly severe form of childhood epilepsy that often resists other therapies.
What Monitoring Looks Like
If you or someone you know is taking felbamate, expect regular blood draws. Full blood counts are recommended before treatment begins, frequently during treatment, and for a significant period after stopping the medication. Liver enzyme levels are also checked at baseline and periodically thereafter. The FDA does not specify an exact testing schedule, leaving that to clinical judgment, but the intent is clear: catch problems early, because both aplastic anemia and liver failure can progress rapidly once they start.
Signs worth paying attention to include unusual bruising or bleeding, persistent fatigue, frequent infections, yellowing of the skin or eyes, dark urine, or upper abdominal pain. These can signal the bone marrow or liver complications that make felbamate uniquely dangerous among seizure medications, even though it sits on no controlled substance list at all.